EAM
ACRS icon

Exome Asset Management’s Aclaris Therapeutics ACRS Stock Holding History

Exome Asset Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-389,333
Closed -$966K – 61
2024
Q4 		$966K Buy
+389,333
New +$969K 0.73% 46

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Exome Asset Management's ACRS Position: Q1 2025 in Review

Exome Asset Management sold out of Aclaris Therapeutics (ACRS) in Q1 2025, closing a stake of 389,333 shares — an estimated $966K sold.

Exome Asset Management first reported a position in ACRS in Q4 2024 and held it in 1 quarter. The position peaked at $966K in Q4 2024. 109 funds tracked by Wall St. Rank hold ACRS as of Q1 2025.

  • Exome Asset Management reported no remaining Aclaris Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Exome Asset Management sold 389,333 Aclaris Therapeutics shares in Q1 2025, an estimated $966K.
  • Exome Asset Management first reported a position in Aclaris Therapeutics in Q4 2024 and held it in 1 quarter.
  • Exome Asset Management's Aclaris Therapeutics position peaked at $966K in Q4 2024.
  • 109 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2025.

Based on Exome Asset Management's 13F filing for Q1 2025, filed 15 May 2025.